Patents by Inventor Brian Addison DECHRISTOPHER

Brian Addison DECHRISTOPHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MALT1 MODULATORS AND USES THEREOF
    Publication number: 20230391781
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
    Type: Application
    Filed: October 15, 2021
    Publication date: December 7, 2023
    Applicant: Rheos Medicines, Inc.
    Inventors: Brian Addison DeChristopher, Guillaume Barbe
  • Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
    Patent number: 11813306
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 14, 2023
    Assignee: Novartis AG
    Inventors: Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Liansheng Su, Lihua Yang, Rui Zheng
  • CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER
    Publication number: 20230089867
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6?, R7, R7?, R8, R9, R9?, R10, R11, R12, and n are described herein.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 23, 2023
    Inventors: Christopher BECKER, Brian Addison DECHRISTOPHER, Alec Nathanson FLYER, Adam FRIEDMAN, Christian GAMPE, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Tyler HARRISON, Qian LIU, Eugene Yuejin LIU, I, Justin Yik Ching MAO, Lauren Gilchrist MONOVICH, Tajesh Jayprakash PATEL, Carina Cristina SANCHEZ, Liansheng SU, Lihua YANG, Rui ZHENG
  • CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
    Publication number: 20210252103
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Application
    Filed: March 12, 2021
    Publication date: August 19, 2021
    Inventors: Karin BRINER, Brian Addison DECHRISTOPHER, Alec Nathanson FLYER, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Eugene Yuejin LIU, Justin Yik Ching MAO, Lauren Gilchrist MONOVICH, Tajesh Jayprakash PATEL, Liansheng SU, Lihua YANG, Rui ZHENG
  • Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
    Patent number: 11026993
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: June 8, 2021
    Assignee: Novartis AG
    Inventors: Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Carina Cristina Sanchez, Liansheng Su, Lihua Yang, Rui Zheng
  • Lipids and lipid compositions for the delivery of active agents
    Patent number: 10844002
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Luis Brito, Brian Addison DeChristopher, Gabriel Grant Gamber, Andrew Geall, Thomas Zabawa
  • CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
    Publication number: 20200164024
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 28, 2020
    Inventors: Karin BRINER, Brian Addison DECHRISTOPHER, Alec Nathanson FLYER, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Eugene Yuejin LIU, Justin Yik Ching MAO, Lauren Gilchrist MONOVICH, Tajesh Jayprakash PATEL, Carina Cristina SANCHEZ, Liansheng SU, Lihua YANG, Rui ZHENG
  • Lipids and Lipid Compositions for the Delivery of Active Agents
    Publication number: 20190002393
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Rohan Eric John BECKWITH, Luis BRITO, Brian Addison DECHRISTOPHER, Gabriel Grant GAMBER, Andrew GEALL, Thomas ZABAWA
  • Lipids and lipid compositions for the delivery of active agents
    Patent number: 10125092
    Abstract: This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: November 13, 2018
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Luis Brito, Brian Addison Dechristopher, Gabriel Grant Gamber, Andrew Geall, Thomas Zabawa
  • Lipids and Lipid Compositions for the Delivery of Active Agents
    Publication number: 20170275243
    Abstract: This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Application
    Filed: September 4, 2015
    Publication date: September 28, 2017
    Applicant: Novartis AG
    Inventors: Rohan Eric John BECKWITH, Luis BRITO, Brian Addison DECHRISTOPHER, Gabriel Grant GAMBER, Andrew GEALL, Thomas ZABAWA